Quince Therapeutics Posts Q2 Loss of $12.31/Share, Extends Cash Runway to 2028
QNCX has more than doubled off its 52-week low of $15.1.
Summary
Quince Therapeutics reported a Q2 net loss of $75.5 million, or $12.31 per share, and extended its cash runway guidance through the end of 2028. The company also provided updated clinical trial timelines for its LAM-001 pulmonary disease program.
Key Events · Earnings and Guidance · QNCX
-
Q2 Net Loss of $75.5M
The net loss of $75.5 million, or $12.31 per share, was driven by a $59 million acquired in-process R&D charge from the Orphai acquisition and a $9.1 million non-cash stock compensation expense.
-
Cash Runway Extended to 2028
Cash and cash equivalents of $116 million as of June 30, 2026, are expected to fund operations through the end of 2028.
-
Clinical Trial Timelines Updated
Phase 2 BOS data are expected in Q1 2027, Phase 2b PH-ILD data in Q1 2028, and the Phase 2 SAPH trial is set to begin in late 2026.
-
Scientific Advisory Board Formed
Five pulmonary medicine experts were appointed to a Scientific Advisory Board to support LAM-001 development.
Analysis · QNCX · Life Sciences
A Q2 net loss of $75.5 million, or $12.31 per share, was driven by a $59 million acquired in-process R&D charge from the Orphai acquisition and a $9.1 million non-cash stock compensation expense. With $116 million in cash, the company expects to fund operations through the end of 2028, providing a clear runway for its pulmonary disease pipeline. Updated clinical timelines were also provided, with Phase 2 BOS data expected in Q1 2027 and Phase 2b PH-ILD data in Q1 2028.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.6% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QNCX was trading at $32.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $33M. The 52-week trading range was $15.10 to $909.98. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.